The proposed mechanism of action for p38 inhibitors in FSHD is to prevent DUX4 expression; however, our data incite the possibility that prevention of apoptosis independent of DUX4 expression might be an additional mechanism by which p38 inhibition can improve muscle pathology in FSHD patients. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.